Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology tags : Vaccine save search
Pneumococcal Vaccine Market, 41% of Growth to Originate from North America, Technavio
Published: 2024-04-16 (Crawled : 22:00) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
pneumococcal vaccine growth
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7448 -3.51% -3.64% 3.1M
|
Health Technology
|
| O: -6.28%
H: 1.25%
C: -13.83%
vaccine results study platform
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | $2.57 -3.57% -3.7% 920K
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.591 -4.68% -4.91% 370K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.49 -2.61% -2.68% 29K
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
VXRT | News | $0.8675 -3.01% -3.1% 1.1M
|
Health Technology
|
| O: 0.0%
H: 7.38%
C: 5.74%
vaccine congress world
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.44 -0.43% -0.44% 2.5M
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
Vaccine Market Insights Revealed in New 2024 Global Industry Report
Published: 2024-03-22 (Crawled : 16:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
report vaccine global market
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $125.37 0.25% 0.1% 6.1M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
CVM | $1.5 -1.32% 0.07% 130K
|
Health Technology
|
| O: 0.0%
H: 1.46%
C: -0.98%
vaccine treat immunology
Veterinary Vaccine Global Market Forecast Report: A $19.86 Billion Market by 2033, Registering 7.3% CAGR During 2023-2033
Published: 2024-03-18 (Crawled : 19:00) - prnewswire.com
ELAN | $13.41 -1.69% -0.45% 4.1M
|
Process Industries
|
| O: -0.63%
H: 0.92%
C: 0.0%
PAHC | $12.9 -0.69% -0.7% 100K
|
Health Technology
|
| O: -0.16%
H: 0.8%
C: -0.08%
veterinary vaccine global market
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | $125.37 0.25% 0.1% 6.1M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
World Vaccine Market Research Report 2023-2024 and 2030 - Increasing Consumer Awareness Towards Immunization Fueling Growth Amid Growing Prevalence of Infectious Diseases
Published: 2024-03-12 (Crawled : 02:00) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
report vaccine world research growing growth market
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ANIX 4 | $3.085 -2.68% -2.76% 73K
|
Health Technology
|
| O: -1.23%
H: 2.18%
C: 0.62%
vaccine congress world presentation
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $175.0 -19.21% 110
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $87.83 3.3% 48K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $105.9 -3.03% 0.07% 12M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine dengue tak-003 qdenga
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.